Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03590821 · ClinicalTrials.gov registry record · Early Phase 1
Timed Aspirin Chronobiome Study
A Early Phase 1 study, sponsored by University of Pennsylvania.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
NCT03590821: Clinical Trial Early Phase 1 study, sponsored by University of Pennsylvania.
NCT03590821 is a Early Phase 1 study that has not yet begun recruiting, run by University of Pennsylvania. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03590821, a Early Phase 1 study, has not yet begun recruiting, sponsored by University of Pennsylvania.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
To determine whether timed administration of aspirin ameliorates the effects of celecoxib on blood pressure.
Interventions
- DRUG Aspirin 81 mg
- DRUG Celecoxib 200mg capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2027-12 |
| Est. Completion | 2028-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03590821
The ClinicalTrials.gov registry entry for NCT03590821 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin 81 mg is the first listed.
NCT03590821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03590821 about?
NCT03590821 is a clinical study titled "Timed Aspirin Chronobiome Study". To determine whether timed administration of aspirin ameliorates the effects of celecoxib on blood pressure.
What is the current status of trial NCT03590821?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2027-12. Estimated completion is 2028-11.
What interventions are being tested in trial NCT03590821?
The interventions under investigation include: Aspirin 81 mg (DRUG), Celecoxib 200mg capsule (DRUG).
Who is sponsoring clinical trial NCT03590821?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.